Literature DB >> 24335307

Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets.

Amy L Hartman1, Diana S Powell, Laura M Bethel, Amy L Caroline, Richard J Schmid, Tim Oury, Douglas S Reed.   

Abstract

Rift Valley fever (RVF) is a veterinary and human disease in Africa and the Middle East. The causative agent, RVF virus (RVFV), can be naturally transmitted by mosquito, direct contact, or aerosol. We sought to develop a nonhuman primate (NHP) model of severe RVF in humans to better understand the pathogenesis of RVF and to use for evaluation of medical countermeasures. NHP from four different species were exposed to aerosols containing RVFV. Both cynomolgus and rhesus macaques developed mild fevers after inhalation of RVFV, but no other clinical signs were noted and no macaque succumbed to RVFV infection. In contrast, both marmosets and African green monkeys (AGM) proved susceptible to aerosolized RVF virus. Fever onset was earlier with the marmosets and had a biphasic pattern similar to what has been reported in humans. Beginning around day 8 to day 10 postexposure, clinical signs consistent with encephalitis were noted in both AGM and marmosets; animals of both species succumbed between days 9 and 11 postexposure. Marmosets were susceptible to lower doses of RVFV than AGM. Histological examination confirmed viral meningoencephalitis in both species. Hematological analyses indicated a drop in platelet counts in both AGM and marmosets suggestive of thrombosis, as well as leukocytosis that consisted mostly of granulocytes. Both AGM and marmosets would serve as useful models of aerosol infection with RVFV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24335307      PMCID: PMC3911574          DOI: 10.1128/JVI.02341-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  Animal models of Rift Valley fever virus infection.

Authors:  Ted M Ross; Nitin Bhardwaj; Stephanie J Bissel; Amy L Hartman; Darci R Smith
Journal:  Virus Res       Date:  2011-11-04       Impact factor: 3.303

2.  Development of a novel nonhuman primate model for Rift Valley fever.

Authors:  Darci R Smith; Brian H Bird; Bridget Lewis; Sara C Johnston; Sarah McCarthy; Ashley Keeney; Miriam Botto; Ginger Donnelly; Joshua Shamblin; César G Albariño; Stuart T Nichol; Lisa E Hensley
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 3.  Breaking the chain: Rift Valley fever virus control via livestock vaccination.

Authors:  Brian H Bird; Stuart T Nichol
Journal:  Curr Opin Virol       Date:  2012-03-29       Impact factor: 7.090

4.  New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2002-05-31

5.  Aerosol infection of cynomolgus macaques with enzootic strains of venezuelan equine encephalitis viruses.

Authors:  Douglas S Reed; Cathleen M Lind; Lawrence J Sullivan; William D Pratt; Michael D Parker
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

6.  The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies.

Authors:  H Hoogstraal; J M Meegan; G M Khalil; F K Adham
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

7.  An epizootic of Rift Valley fever in Egypt in 1977.

Authors:  J M Meegan; H Hoogstraal; M I Moussa
Journal:  Vet Rec       Date:  1979-08-11       Impact factor: 2.695

8.  Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys.

Authors:  J C Morrill; C J Peters
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

9.  Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics.

Authors:  Tariq A Madani; Yagob Y Al-Mazrou; Mohammad H Al-Jeffri; Amin A Mishkhas; Abdullah M Al-Rabeah; Adel M Turkistani; Mohammad O Al-Sayed; Abdullah A Abodahish; Ali S Khan; Thomas G Ksiazek; Osama Shobokshi
Journal:  Clin Infect Dis       Date:  2003-09-23       Impact factor: 9.079

10.  Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus.

Authors:  Jacquelyn M Bales; Diana S Powell; Laura M Bethel; Douglas S Reed; Amy L Hartman
Journal:  Front Cell Infect Microbiol       Date:  2012-08-02       Impact factor: 5.293

View more
  34 in total

1.  Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats.

Authors:  Aaron W Walters; Michael R Kujawa; Joseph R Albe; Douglas S Reed; William B Klimstra; Amy L Hartman
Journal:  Virology       Date:  2018-11-02       Impact factor: 3.616

Review 2.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

Review 3.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

4.  Generation and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber.

Authors:  J Kyle Bohannon; Matthew G Lackemeyer; Jens H Kuhn; Jiro Wada; Laura Bollinger; Peter B Jahrling; Reed F Johnson
Journal:  Inhal Toxicol       Date:  2015-05-13       Impact factor: 2.724

5.  Widespread Virus Replication in Alveoli Drives Acute Respiratory Distress Syndrome in Aerosolized H5N1 Influenza Infection of Macaques.

Authors:  Elizabeth R Wonderlich; Zachary D Swan; Stephanie J Bissel; Amy L Hartman; Jonathan P Carney; Katherine J O'Malley; Adebimpe O Obadan; Jefferson Santos; Reagan Walker; Timothy J Sturgeon; Lonnie J Frye; Pauline Maiello; Charles A Scanga; Jennifer D Bowling; Anthea L Bouwer; Parichat A Duangkhae; Clayton A Wiley; JoAnne L Flynn; Jieru Wang; Kelly S Cole; Daniel R Perez; Douglas S Reed; Simon M Barratt-Boyes
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

6.  Lrp1 is a host entry factor for Rift Valley fever virus.

Authors:  Safder S Ganaie; Madeline M Schwarz; Cynthia M McMillen; David A Price; Annie X Feng; Joseph R Albe; Wenjie Wang; Shane Miersch; Anthony Orvedahl; Aidan R Cole; Monica F Sentmanat; Nawneet Mishra; Devin A Boyles; Zachary T Koenig; Michael R Kujawa; Matthew A Demers; Ryan M Hoehl; Austin B Moyle; Nicole D Wagner; Sarah H Stubbs; Lia Cardarelli; Joan Teyra; Anita McElroy; Michael L Gross; Sean P J Whelan; John Doench; Xiaoxia Cui; Tom J Brett; Sachdev S Sidhu; Herbert W Virgin; Takeshi Egawa; Daisy W Leung; Gaya K Amarasinghe; Amy L Hartman
Journal:  Cell       Date:  2021-09-23       Impact factor: 66.850

7.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

8.  Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.

Authors:  Elizabeth R Wonderlich; Amy L Caroline; Cynthia M McMillen; Aaron W Walters; Douglas S Reed; Simon M Barratt-Boyes; Amy L Hartman
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

9.  The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Authors:  Shoko Nishiyama; Nandadeva Lokugamage; Tetsuro Ikegami
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

10.  Development of Rift valley fever encephalitis in rats is mediated by early infection of olfactory epithelium and neuroinvasion across the cribriform plate.

Authors:  Devin A Boyles; Madeline M Schwarz; Joseph R Albe; Cynthia M McMillen; Katherine J O'Malley; Douglas S Reed; Amy L Hartman
Journal:  J Gen Virol       Date:  2021-02       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.